Guy joined Isogenica as CSO in January 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development. At Isogenica, he leads the internal technology and product development, as well as drive scientific interactions with prospective or current licensees and other partners.
In his previous position as Research Fellow at Ablynx, he conceived of many of its internal drug development programs, leading a number of them through the early R&D stages as well. He was also responsible for a number of technology development programs to enable lead generation to challenging targets, or enable novel applications for domain antibodies.
During his academic training, Guy did research in the pathogenesis and immunotherapy of autoimmune and inflammatory disorders, ranging from cell-based immunotherapy clinical trials in Multiple Sclerosis patients (PhD, University of Hasselt) to preclinical in vitro/in vivo target discovery and validation work as postdoc at Stanford University Medical School.